Management of Decreased Gabapentin Efficacy in Diabetic Neuropathy and Sciatica

Understanding the Current Situation

The American Academy of Neurology recommends titrating gabapentin upward to 1800-3600 mg/day divided into three doses for neuropathic pain relief, as the current dose of 300mg/day is inadequate 1, 2
Gabapentin 300mg/day is essentially a sub-therapeutic dose, with the evidence-based target range for diabetic neuropathy being 1800-3600 mg/day 1, 2, 3

The American Academy of Neurology recommends a gradual titration approach, increasing gabapentin by 100-300mg every 1-7 days as tolerated 1
An adequate trial requires 3-8 weeks for titration plus 2 weeks at maximum tolerated dose before concluding the medication is ineffective 1, 2

The American Geriatrics Society recommends checking renal function before aggressive titration of gabapentin, as it requires dose reduction in renal impairment 1, 4

The American Academy of Neurology suggests switching to pregabalin if gabapentin is ineffective, starting at 50mg three times daily and titrating to 300-600mg/day 2, 5
Pregabalin offers easier titration and more predictable pharmacokinetics than gabapentin, with a Number Needed to Treat (NNT) of 4.04 at 600mg/day 2, 4, 5
Duloxetine is also an alternative, starting at 60mg daily and increasing to 120mg daily, with an NNT of 5.2 for 60mg/day and 4.9 for 120mg/day 1, 2, 6
Tricyclic antidepressants, such as amitriptyline, can be used as a third alternative, but are contraindicated in patients with cardiovascular disease, glaucoma, or orthostatic hypotension 1, 6